Openbookopenbook
Equity
Viaderma Inc(VDRM)
USD --+0.00%
Reward63Moderate
Risk53Moderate
📊75%Data
Revenue down 58% YoY
VDRM
+0.0 · +0.00%
USD · PINK
Viaderma Inc | Healthcare
Profitless Growth
Market Cap:493485
ℹ️
Reward Rating
63
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
53
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on VDRM to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Viaderma Inc?

, through its subsidiary, manufactures and sells pharmaceutical related products in the United States.

VDRM · Verdict

Solid reward · elevated risk

VDRM stands out on volatility and growth, but watch the balance sheet signal.

Based on 88% data coverage

VDRM · Verdict

What’s working & what to watch

Strengths 2

  • Volatility95/100

    Top decile vs peers

  • Growth89/100

    Revenue +274.1% CAGR

Watchouts 4

  • Balance sheet31/100

    Interest covered 1.1×

  • Cash flow36/100

    0% free-cash-flow margin

  • Valuation42/100

    Below average

  • Profitability45/100

    1% net margin · 0% ROE

Model-based scoring. For information only — not financial advice.

What is Viaderma Inc?

, through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company's lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 493.49K.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (63)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap493.49K
P/E Ratio0.04
Dividend YieldN/A
52 Week High0.024
52 Week Low0.0001
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding1B
No. of EmployeesN/A
IndustryDrug Manufacturers - Specialty & Generic
ExchangePINK
Beta0.12
CurrencyUSD
Websiteviaderma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.